Pharmaceutical Industry Today

Chronic Pain Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Common types of chronic pain include migraines, back pain, arthritis, neuropathic pain, etc. Chronic pain can also occur after an injury or major surgery. Chronic pain can be treated either by drugs or devices.
Published 23 February 2024

Chronic Pain Treatment Market

Global Chronic Pain Treatment Market Projected to Surpass US$ 143.2 Billion by 2030, Propelled by a 7.1% CAGR

The Global Chronic Pain Treatment Market exhibited a robust growth trajectory, reaching a valuation of US$ 83.8 billion in 2022. Anticipated to soar further, the market is projected to achieve a staggering US$ 143.2 billion by 2030, registering a Compound Annual Growth Rate (CAGR) of 7.1% during the forecast period from 2024 to 2031.

Chronic pain, manifesting in forms such as migraines, back pain, arthritis, and neuropathic pain, remains a pervasive health concern. This persistent condition may arise post-injury or major surgery, necessitating effective treatment options. The market primarily relies on pharmaceuticals and advanced devices to address this global health challenge.

Key Market Dynamics and Trends

Opioids, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), anticonvulsants, and antidepressants stand out as the predominant pharmacological interventions for chronic pain management. The market is bolstered by compelling growth drivers, including the escalating prevalence of chronic diseases, a burgeoning geriatric population, technological advancements, increasing clinical trials, and growing FDA approvals.

Market Scope and Metrics

CAGR: 7.1%

Size Available for Years: 2021-2030

Forecast Period: 2024-2031

Segments Covered: Indication, Product Type, Distribution Channel, and Region

Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Fastest Growing Region: Asia-Pacific

Largest Region: North America

Insights Covered in the Report:

The comprehensive report encompasses various facets of the Chronic Pain Treatment Market, including Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and other key insights.


To know more Insights Download Sample


Recent Advancements Driving Market Growth

In particular, the market is witnessing a surge in FDA approvals for neurostimulation devices, exemplified by Neuspera Medical's recent achievement. The US-based neuromodulation devices maker received FDA approval for its next-generation Neuspera ultra-miniaturized system on March 23, 2023. This innovative system delivers peripheral nerve stimulation (PNS) through a wireless, less invasive, and versatile platform, enhancing patient experience and procedural flexibility.

Clinical Trials and Challenges

The market is further influenced by increasing clinical trials, such as Tufts University's exploration of immersive virtual reality as a treatment for chronic back pain. However, the complexity of diagnosing and treating neuropathic pain poses challenges to market growth, as highlighted in an article published on April 23, 2023.

Segment Analysis

The global chronic pain treatment market is segmented based on product type, indication, distribution channel, and region. The Neuropathic Pain segment, accounting for approximately 42.3% of the market share, is driven by factors like the increasing prevalence of chronic diseases like diabetes and rising clinical trials.

Geographical Share

North America dominates the market, contributing to about 39.6% of the market share in 2022. This is attributed to increasing research and development activities and a well-established healthcare infrastructure, fostering the adoption of cutting-edge treatments.

Major Players

Key global players shaping the Chronic Pain Treatment Market include Pfizer Inc., Abbott Laboratories, Eli Lilly and Company, Novartis AG, Johnson & Johnson, Sanofi SA, Teva Pharmaceutical Industries Ltd, Baxter International, Merck & Co. Inc, Boston Scientific Corporation, among others.

Related Reports:

athletes foot drugs market

lice treatment market

diabetic ketoacidosis market

diabetic gastroparesis treatment market

diabetic neuropathic pain market

iron deficiency anemia market

About Us -

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us -

Company Name: DataM Intelligence

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com

Other Industry News

Ready to start publishing

Sign Up today!